Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.

Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ.

Leukemia. 2019 Mar 11. doi: 10.1038/s41375-019-0435-7. [Epub ahead of print]

PMID:
30858549
2.

The challenges of checkpoint inhibition in the treatment of multiple myeloma.

Paul B, Kang S, Zheng Z, Kang Y.

Cell Immunol. 2018 Dec;334:87-98. doi: 10.1016/j.cellimm.2018.10.003. Epub 2018 Oct 13. Review.

PMID:
30342750
3.

Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.

Zheng J, Sha Y, Roof L, Foreman O, Lazarchick J, Venkta JK, Kozlowski C, Gasparetto C, Chao N, Ebens A, Hu J, Kang Y.

Cancer Lett. 2019 Jan;440-441:1-10. doi: 10.1016/j.canlet.2018.10.003. Epub 2018 Oct 9.

PMID:
30312729
4.

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.

Sivaraj D, Green MM, Kang Y, Long GD, Rizzieri DA, Li Z, Garrett AH, McIntyre JL, Chao NJ, Gasparetto C.

Blood Cancer J. 2018 Jul 31;8(8):71. doi: 10.1038/s41408-018-0104-5. No abstract available.

5.
6.

Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma.

Zheng Z, Fan S, Zheng J, Huang W, Gasparetto C, Chao NJ, Hu J, Kang Y.

J Hematol Oncol. 2018 Feb 27;11(1):29. doi: 10.1186/s13045-018-0575-7.

7.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, Chandler JC, Costello C, Faiman M, Fung HC, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kang Y, Kassim A, Liedtke M, Malek E, Martin T, Neppalli VT, Omel J, Raje N, Singhal S, Somlo G, Stockerl-Goldstein K, Weber D, Yahalom J, Kumar R, Shead DA.

J Natl Compr Canc Netw. 2018 Jan;16(1):11-20. doi: 10.6004/jnccn.2018.0002.

PMID:
29295877
8.

Thioredoxin mitigates radiation-induced hematopoietic stem cell injury in mice.

Sundaramoorthy P, Wang Q, Zheng Z, Jiao Y, Chen BJ, Doan PL, Chao NJ, Kang Y.

Stem Cell Res Ther. 2017 Nov 15;8(1):263. doi: 10.1186/s13287-017-0711-2.

9.

Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone ("VCD-Lite") in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma.

Tuchman SA, Moore JO, DeCastro CD, Li Z, Sellars E, Kang Y, Long G, Gasparetto CG.

J Geriatr Oncol. 2017 May;8(3):165-169. doi: 10.1016/j.jgo.2017.02.004. Epub 2017 Feb 28.

PMID:
28256432
10.

Pim1 kinase regulates c-Kit gene translation.

An N, Cen B, Cai H, Song JH, Kraft A, Kang Y.

Exp Hematol Oncol. 2016 Dec 30;5:31. doi: 10.1186/s40164-016-0060-3. eCollection 2016.

11.

Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.

Sivaraj D, Green MM, Li Z, Sung AD, Sarantopoulos S, Kang Y, Long GD, Horwitz ME, Lopez RD, Sullivan KM, Rizzieri DA, Chao NJ, Gasparetto C.

Biol Blood Marrow Transplant. 2017 Feb;23(2):262-268. doi: 10.1016/j.bbmt.2016.11.010. Epub 2016 Nov 14.

12.

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery.

Green MM, Chao N, Chhabra S, Corbet K, Gasparetto C, Horwitz A, Li Z, Venkata JK, Long G, Mims A, Rizzieri D, Sarantopoulos S, Stuart R, Sung AD, Sullivan KM, Costa L, Horwitz M, Kang Y.

J Hematol Oncol. 2016 Aug 17;9(1):71. doi: 10.1186/s13045-016-0301-2.

13.
14.

Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.

Venkata JK, An N, Stuart R, Costa LJ, Cai H, Coker W, Song JH, Gibbs K, Matson T, Garrett-Mayer E, Wan Z, Ogretmen B, Smith C, Kang Y.

Blood. 2014 Sep 18;124(12):1915-25.

15.

Thioredoxin and hematologic malignancies.

An N, Kang Y.

Adv Cancer Res. 2014;122:245-79. doi: 10.1016/B978-0-12-420117-0.00007-4.

PMID:
24974184
16.

Similar dynamics of intraapheresis autologous CD34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixafor.

Schade H, Chhabra S, Kang Y, Stuart RK, Edwards KH, Kramer C, Butcher C, Littleton A, Schneider M, Budisavljevic MN, Costa LJ.

Transfusion. 2014 Dec;54(12):3131-7. doi: 10.1111/trf.12761. Epub 2014 Jun 19.

PMID:
24947954
17.

Fact or fiction--identifying the elusive multiple myeloma stem cell.

Kellner J, Liu B, Kang Y, Li Z.

J Hematol Oncol. 2013 Dec 7;6:91. doi: 10.1186/1756-8722-6-91. Review.

18.

Plasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms.

Coker WJ, Jeter A, Schade H, Kang Y.

Biomark Res. 2013 Feb 4;1(1):8. doi: 10.1186/2050-7771-1-8.

19.

Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratification.

Costa LJ, Nista EJ, Buadi FK, Lacy MQ, Dispenzieri A, Kramer CP, Edwards KH, Kang Y, Gertz MA, Stuart RK, Kumar S.

Biol Blood Marrow Transplant. 2014 Feb;20(2):222-8. doi: 10.1016/j.bbmt.2013.11.003. Epub 2013 Nov 6.

20.

Proteomic analysis of murine bone marrow niche microenvironment identifies thioredoxin as a novel agent for radioprotection and for enhancing donor cell reconstitution.

An N, Janech MG, Bland AM, Lazarchick J, Arthur JM, Kang Y.

Exp Hematol. 2013 Nov;41(11):944-56. doi: 10.1016/j.exphem.2013.08.004. Epub 2013 Aug 27.

21.
22.

Pim1 serine/threonine kinase regulates the number and functions of murine hematopoietic stem cells.

An N, Lin YW, Mahajan S, Kellner JN, Wang Y, Li Z, Kraft AS, Kang Y.

Stem Cells. 2013 Jun;31(6):1202-12. doi: 10.1002/stem.1369.

23.

Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice.

An N, Kraft AS, Kang Y.

J Hematol Oncol. 2013 Jan 29;6:12. doi: 10.1186/1756-8722-6-12.

24.

Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy.

Jeter A, Kang Y.

Exp Hematol Oncol. 2012 Aug 15;1(1):20. doi: 10.1186/2162-3619-1-20.

25.

Insulin-like growth factor 1 mitigates hematopoietic toxicity after lethal total body irradiation.

Zhou D, Deoliveira D, Kang Y, Choi SS, Li Z, Chao NJ, Chen BJ.

Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1141-8. doi: 10.1016/j.ijrobp.2012.08.014. Epub 2012 Sep 25.

26.

Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange.

Costa LJ, Abbas J, Ortiz-Cruz KL, Kang Y, Stuart RK.

Eur J Haematol. 2012 Nov;89(5):432-4. doi: 10.1111/ejh.12008. Epub 2012 Sep 13. No abstract available.

PMID:
22971164
27.

Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patients.

Butler C, Wolff DJ, Kang Y, Stuart RK, Costa LJ.

Leuk Lymphoma. 2012 Dec;53(12):2444-8. doi: 10.3109/10428194.2012.691483. Epub 2012 May 31.

PMID:
22574971
28.

Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.

Costa LJ, Kramer C, Hogan KR, Butcher CD, Littleton AL, Shoptaw KB, Kang Y, Stuart RK.

Transfusion. 2012 Nov;52(11):2375-81. doi: 10.1111/j.1537-2995.2012.03579.x. Epub 2012 Mar 8.

PMID:
22404694
29.

Selective enhancement of donor hematopoietic cell engraftment by the CXCR4 antagonist AMD3100 in a mouse transplantation model.

Kang Y, Chen BJ, Deoliveira D, Mito J, Chao NJ.

PLoS One. 2010 Jun 28;5(6):e11316. doi: 10.1371/journal.pone.0011316.

30.

Unmanipulated or CD34 selected haplotype mismatched transplants.

Kang Y, Chao NJ, Aversa F.

Curr Opin Hematol. 2008 Nov;15(6):561-7. doi: 10.1097/MOH.0b013e32831366eb. Review.

PMID:
18832926
31.

Integration site choice of a feline immunodeficiency virus vector.

Kang Y, Moressi CJ, Scheetz TE, Xie L, Tran DT, Casavant TL, Ak P, Benham CJ, Davidson BL, McCray PB Jr.

J Virol. 2006 Sep;80(17):8820-3.

32.

Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer.

Kang Y, Xie L, Tran DT, Stein CS, Hickey M, Davidson BL, McCray PB Jr.

Blood. 2005 Sep 1;106(5):1552-8. Epub 2005 May 10.

33.

CCL20 is an inducible product of human airway epithelia with innate immune properties.

Starner TD, Barker CK, Jia HP, Kang Y, McCray PB Jr.

Am J Respir Cell Mol Biol. 2003 Nov;29(5):627-33. Epub 2003 May 14.

PMID:
12748059
34.

In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins.

Kang Y, Stein CS, Heth JA, Sinn PL, Penisten AK, Staber PD, Ratliff KL, Shen H, Barker CK, Martins I, Sharkey CM, Sanders DA, McCray PB Jr, Davidson BL.

J Virol. 2002 Sep;76(18):9378-88.

35.

Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases.

Melo ME, Qian J, El-Amine M, Agarwal RK, Soukhareva N, Kang Y, Scott DW.

J Immunol. 2002 May 1;168(9):4788-95.

Supplemental Content

Loading ...
Support Center